BACKGROUND AND PURPOSE: TO901317, a synthetic liver X receptor agonist, elevates high-density lipoprotein cholesterol (HDL-C) in mice. We tested the hypothesis that TO901317 treatment of stroke promotes angiogenesis and vascular maturation and improves functional outcome after stroke by increasing endothelial nitric oxide synthase (eNOS) phosphorylation. METHODS: C57BL/6J mice were subjected to middle cerebral artery occlusion and were treated with or without TO901317 (30 mg/kg) starting 24 hours after middle cerebral artery occlusion and daily for 14 days. RESULTS: TO901317 significantly increased serum HDL-C level, promoted angiogenesis and vascular stabilization in the ischemic brain, and improved functional outcome after stroke. The increased HDL-C level significantly correlated with functional recovery after stroke. TO901317 also increased eNOS phosphorylation in the ischemic brain. Mechanisms underlying the TO901317-induced angiogenesis were investigated using eNOS knockout (eNOS-/-) mice. TO901317 treatment of eNOS-/- mice significantly increased HDL-C level but failed to increase angiogenesis and functional outcome after stroke. In vitro studies demonstrated that TO901317 and HDL-C significantly increased capillary tube formation and promoted eNOS phosphorylation activity in cultured mouse brain endothelial cells compared with nontreatment controls. However, TO901317 and high-density lipoprotein treatment-induced capillary tube formation were absent in eNOS-deficient mouse brain endothelial cell. CONCLUSIONS: These data indicate that TO901317 treatment increases serum HDL-C level, which promotes angiogenesis through eNOS and leads to improvement of functional outcome after stroke.
BACKGROUND AND PURPOSE: TO901317, a synthetic liver X receptor agonist, elevates high-density lipoprotein cholesterol (HDL-C) in mice. We tested the hypothesis that TO901317 treatment of stroke promotes angiogenesis and vascular maturation and improves functional outcome after stroke by increasing endothelial nitric oxide synthase (eNOS) phosphorylation. METHODS: C57BL/6J mice were subjected to middle cerebral artery occlusion and were treated with or without TO901317 (30 mg/kg) starting 24 hours after middle cerebral artery occlusion and daily for 14 days. RESULTS: TO901317 significantly increased serum HDL-C level, promoted angiogenesis and vascular stabilization in the ischemic brain, and improved functional outcome after stroke. The increased HDL-C level significantly correlated with functional recovery after stroke. TO901317 also increased eNOS phosphorylation in the ischemic brain. Mechanisms underlying the TO901317-induced angiogenesis were investigated using eNOS knockout (eNOS-/-) mice. TO901317 treatment of eNOS-/- mice significantly increased HDL-C level but failed to increase angiogenesis and functional outcome after stroke. In vitro studies demonstrated that TO901317 and HDL-C significantly increased capillary tube formation and promoted eNOS phosphorylation activity in cultured mouse brain endothelial cells compared with nontreatment controls. However, TO901317 and high-density lipoprotein treatment-induced capillary tube formation were absent in eNOS-deficient mouse brain endothelial cell. CONCLUSIONS: These data indicate that TO901317 treatment increases serum HDL-C level, which promotes angiogenesis through eNOS and leads to improvement of functional outcome after stroke.
Authors: Satoshi Kashiwagi; Yotaro Izumi; Takeshi Gohongi; Zoe N Demou; Lei Xu; Paul L Huang; Donald G Buerk; Lance L Munn; Rakesh K Jain; Dai Fukumura Journal: J Clin Invest Date: 2005-06-09 Impact factor: 14.808
Authors: Jesús R Morales; Iván Ballesteros; José Manuel Deniz; Olivia Hurtado; José Vivancos; Florentino Nombela; Ignacio Lizasoain; Antonio Castrillo; María A Moro Journal: Circulation Date: 2008-09-15 Impact factor: 29.690
Authors: Reena Sandhu; Krystyna Teichert-Kuliszewska; Sukriti Nag; Gerald Proteau; Malcolm J Robb; Andrew I M Campbell; Michael A Kuliszewski; Michael J B Kutryk; Duncan J Stewart Journal: Cardiovasc Res Date: 2004-10-01 Impact factor: 10.787
Authors: Maria E Rämet; Mika Rämet; Qing Lu; Moriah Nickerson; Markku J Savolainen; Amy Malzone; Richard H Karas Journal: J Am Coll Cardiol Date: 2003-06-18 Impact factor: 24.094
Authors: Elvin Tyrone Price; Michael A Pacanowski; Michael A Martin; Rhonda M Cooper-DeHoff; Carl J Pepine; Issam Zineh; Julie A Johnson Journal: Pharmacogenet Genomics Date: 2011-06 Impact factor: 2.089
Authors: Karen Gertz; Golo Kronenberg; Roland E Kälin; Tina Baldinger; Christian Werner; Mustafa Balkaya; Gina D Eom; Julian Hellmann-Regen; Jan Kröber; Kelly R Miller; Ute Lindauer; Ulrich Laufs; Ulrich Dirnagl; Frank L Heppner; Matthias Endres Journal: Brain Date: 2012-04-03 Impact factor: 13.501